Symphogen Launches New Website and Marketing Materials
News Dec 21, 2005
Symphogen has recently launched a new website accompanied by several new factsheets detailing the company, technology and products.
Symphogen’s recombinant polyclonal antibody products are geared to the treatment of diseases caused by complex target antigens such as cancer, infectious diseases, transplantation rejection, and allergy.
The Company’s lead product, which combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN), is expected to enter the clinic in 2006.
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019